Riskpilot← Back to searchSign inGet full accessSandvig-Pharma ApS
APSActiveCVR 40667687Kirkeplads 8Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20192 employees
Revenue 2025
DKK -4,5M
+38% vs 2024
EBITDA margin
112.6%
-50% vs 2024
Equity ratio
-246.5%
Financial strength
Net profit 2025
DKK -4M
+28% vs 2024
| Revenue | DKK -4,5M | +38% |
| EBITDA | DKK -5,1M | -50% |
| Net profit | DKK -4M | +28% |
| Total assets | DKK 7,2M | +15% |
| Equity | DKK -17,8M | -29% |
| Employees | 2 | — |
Legal name
Sandvig-Pharma ApS
CVR number
40667687
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
12. juli 2019
Share capital
DKK 50.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at drive virksomhed med produktion, markedsføring og salg af dyner, puder og lignende.
Address
Kirkeplads 8
Phone
+4530580398
Email
lbd@sandvigcapital.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | — | — | -423 | -1.235 | -3.283 | -4.539 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -116 | -572 |
| EBITDA | 0 | 0 | 0 | -423 | -1.235 | -3.399 | -5.112 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 0 | 0 | 0 | -423 | -1.235 | -3.399 | -5.112 |
| Net financials | 0 | 0 | 0 | 0 | -2 | -2 | -1 |
| Profit before tax | 0 | 0 | 0 | -734 | -9.954 | -7.135 | -5.113 |
| Tax | -0 | -0 | -0 | -162 | -2.190 | -1.569 | -1.125 |
| Net profit | 0 | 0 | 0 | -573 | -7.764 | -5.566 | -3.988 |
| Item | 2020 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 50 | 50 | 50 | 354 | 3.426 | 6.292 | 7.237 |
| Equity | 50 | 50 | 50 | -523 | -8.288 | -13.854 | -17.842 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 877 | 11.714 | 20.146 | 25.079 |
| Total debt | 0 | 0 | 0 | 877 | 11.714 | 20.146 | 25.079 |
EBITDA margin
-511159300.0%
This company
15.8%
Market median
-3235185543% vs market
20202025
Equity ratio
-246.5%
This company
38.2%
Market median
-745% vs market
20202025
Return on equity
-398802900.0%
This company
18.4%
Market median
-2167407165% vs market
20202025
Net profit margin
-398802900.0%
This company
8.1%
Market median
-4923492693% vs market
20202025
Asset turnover
-0.63×
This company
1.12×
Market median
-156% vs market
20202025
Debt / equity
1.41×
This company
0.62×
Market median
-127% vs market
20202025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2021-05-01 – 2021-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-05-01 – 2021-04-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-12 – 2020-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JB Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
GN Founder | Founder | 2019 | — | — |
LB Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Sandvig Capital ApS | Company | 100.0% | 100.0% | 2022 |
Denker Invest ApS | Company | 100.0% | 100.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
JBD, Aabenraa ApS
Sandvig-Pharma ApS Board members of Sandvig-Pharma ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jeannette Buchard Denker | Chief Executive Officer | 0 companies |
| Gunhild Nyborg Pedersen | Founder | 0 companies |
| Lars Buchard Denker | Chief Executive Officer | 0 companies |